BTIG analyst Matthew Vanvliet upgrades Agilysys (NASDAQ:AGYS) from Neutral to Buy.
Astellas Entered Into Definitive Agreement to Acquire Iveric Bio for $40/Share In Cash
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO: Glenn P.